Drug Report History #2471

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v3-FR
Language (Changed) Updated to: English Was: French
Date Updated (Changed) Updated to: 2017-04-26 Was: 2017-04-06
Drug Identification Number (Changed) Updated to: 02300206 Was: 02373130
Brand name (Changed) Updated to: SEROQUEL XR Was: XYLOCAINE 2% WITH EPINEPHRINE 1:200000
Common or Proper name (Changed) Updated to: quetiapine fumarate extended-release tablets Was: Lidocaine Hydrochloride and Epinephrine Bitartrate Injection
Company Name (Changed) Updated to: CHEPLAPHARM ARZNEIMITTEL GMBH Was: ASPEN PHARMACARE CANADA INC.
Ingredients (Changed) Updated to: QUETIAPINE Was: LIDOCAINE HYDROCHLORIDE EPINEPHRINE RACEMIC
Strength(s) (Changed) Updated to: 300MG Was: 20MG 0.005MG
Dosage form(s) (Changed) Updated to: TABLET (EXTENDED-RELEASE) Was: SOLUTION
Route of administration (Changed) Updated to: ORAL Was: BLOCK/INFILTRATION
Packaging size (Changed) Updated to: 60 tablets Was: 20 mL
Additional packaging sizes
ATC code (Changed) Updated to: N05AH Was: N01BB
ATC description (Changed) Updated to: ANTIPSYCHOTICS Was: ANESTHETICS, LOCAL
Reason for shortage (Changed) Updated to: Demand increase for the drug. Was: Delay in shipping of the drug.
Anticipated start date (Changed) Updated to: 2017-04-24 Was:
Actual start date (Changed) Updated to: Was: 2017-04-05
Estimated end date (Changed) Updated to: Unknown Was: 2017-04-21
Actual end date (Changed) Updated to: 2017-04-26 Was:
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments